The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2018 | An exciting era for CAR T-cell therapy
Mohamad Mohty, MD, PhD, of the University Pierre & Marie Curie, Paris, France, discusses the promising translation of treatments, notably the efficacy and feasibility of CAR-T cell therapy outside the clinical trial setting. Speaking from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, Prof. Mohty also shares his excitement in the progression of next-generation allogeneic T-cell immunotherapies for the treatment of Epstein–Barr virus (EBV) associated post-transplant lymphoproliferative disorder (PTLD).
